Hemophilia A
Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial
Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination
FDA Approves Alhemo: A Breakthrough Once-Daily Treatment for Hemophilia A and B with Inhibitors
Alhemo, FDA approval, hemophilia A, hemophilia B, inhibitors, concizumab, once-daily treatment, subcutaneous injection, prophylactic treatment
Roche Discontinues Second Hemophilia A Gene Therapy Candidate Under Spark Amid Shift in Hematologic Portfolio
Roche, Spark Therapeutics, Hemophilia A, Gene Therapy, RG6358, SPK-8016, Hemlibra, SPK-8011
Novo Nordisk Invests $1.2 Billion in New Danish Production Facility for Rare Disease Therapies
Novo Nordisk, rare disease drugs, Denmark, production facility, investment, hemophilia, pharmaceutical manufacturing
Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval
Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen
Pfizer’s HYMPAVZI Receives FDA Approval for Hemophilia A and B Treatment
HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor
Pfizer Secures Second FDA Approval for Hemophilia Treatment in Six Months
Pfizer, FDA approval, Hemophilia, Gene Therapy, Hemophilia B, HYMPAVZI
BioMarin Announces Significant Workforce Reduction Amid Restructuring Efforts
BioMarin, layoffs, restructuring, biotech, rare diseases, gene therapy, Roctavian, hemophilia A
BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp
BioMarin, executive restructuring, Amgen, Roche, Greg Friberg, James Sabry, Roctavian, hemophilia A gene therapy